Aurinia Pharmaceuticals Inc (FRA:IKAP)
€ 8.542 -0.116 (-1.34%) Market Cap: 1.23 Bil Enterprise Value: 978.48 Mil PE Ratio: 0 PB Ratio: 3.30 GF Score: 81/100

Q1 2022 Aurinia Pharmaceuticals Inc Earnings Call Transcript

May 10, 2022 / 12:30PM GMT
Release Date Price: €8.48 (-9.56%)
Operator

Greetings and welcome to the Aurinia Pharmaceuticals' first quarter 2022 financial and operational results conference call. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the conference over to your host Dana Lynch, Aurinia's Senior Director of Corporate Communications and Corporate Affairs. Thank you. Dana. You may begin.

Dana Lynch
Aurinia Pharmaceuticals Inc. - Director of Corporate Communications

Thank you, Jim. And thank you all for joining today's call and webcast to discuss Aurinia's first quarter 2022 financial results. Joining me this morning are Peter Greenleaf, President and CEO, Joe Miller, Chief Financial Officer. So will be both whom will be leading the call. Other members of the executive team, specifically Max Colao Chief Commercial Officer and Dr Neil Solomons, Chief Medical Officer will also be available at the conclusion of our prepared remarks for the Q&A portion of the call.

This morning, we issued a press release, announcing our financial results and recent operational

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot